10x Genomics, Inc.
As of Oct 22, 2026, 10x Genomics is in Stage 2, the uptrend phase, now in week 48 (since Nov 12, 2025). It closed at $69.75, 28.6% below its 52-week high and above its 200-day average, which is rising.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and th… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care
Is TXG early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
TXG among Medical Devices1st of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
10x Genomics: quick answers
What stage is 10x Genomics in?
As of Oct 22, 2026, 10x Genomics (TXG) is in Stage 2, the uptrend phase. It entered Stage 2 on Nov 12, 2025 and is in week 48. What the four stages mean
Is 10x Genomics in an uptrend?
Yes. 10x Genomics is in a Stage 2 uptrend. It trades 79.4% above its 200-day average, which is rising.
How far is 10x Genomics from its 52-week high?
10x Genomics closed at $69.75 on Oct 22, 2026, 28.6% below its 52-week high of $97.74. Its 52-week low is $12.26.
How has 10x Genomics performed over the past year?
As of Oct 22, 2026, 10x Genomics is up 435.3% over the past year and up 319.7% so far in 2026.
Which sector and industry is 10x Genomics in?
10x Genomics is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.